![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/asset/a5db3686-c528-4236-93cf-6855cbd7db92/gr1.jpg)
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
![Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm715152e1_BivalentVaccineEffectiveness_IMAGE_16Dec2022_1200x675.jpg?_=42783)
Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022 | MMWR
![LVHN Offering Second Dose of Bivalent COVID-19 Booster Shot for Both 65+ and Immunocompromised People LVHN Offering Second Dose of Bivalent COVID-19 Booster Shot for Both 65+ and Immunocompromised People](https://www.lvhn.org/sites/default/files/2023-05/N23855_Bivalent%20Booster%20Update-Press%20Release.jpg)
LVHN Offering Second Dose of Bivalent COVID-19 Booster Shot for Both 65+ and Immunocompromised People
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations](https://pub.mdpi-res.com/vaccines/vaccines-11-00906/article_deploy/html/images/vaccines-11-00906-g001-550.jpg?1682593767)
Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
![Second bivalent booster: Sandra Fryhofer, MD, on who should get another COVID shot and when - YouTube Second bivalent booster: Sandra Fryhofer, MD, on who should get another COVID shot and when - YouTube](https://i.ytimg.com/vi/ZlrewJP4e5g/maxresdefault.jpg)